FDA approves Cordis Bx Velocity stent:
This article was originally published in Clinica
Executive Summary
The US FDA has approved Cordis' PMA supplement to expand the use of its Bx Velocity coronary artery stent to include the elective treatment of de novo and restenotic lesions in native arteries. The product was previously approved for the treatment of lesions considered to be at immediate risk of complete closure. Cordis, a Johnson & Johnson subsidiary, claims the product is available in the broadest range of diameters for coronary arteries in the industry.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.